​The purpose of this memo is to inform Pre-Exposure Prophylaxis Assistance Program (PrEP-AP) Enrollment Workers (EWs) that Gilead's Advancing Access® Patient Assistance Program (PAP) will no longer accept new enrollments for coverage of emtricitabine-tenofovir (TDF), brand name Truvada®, after December 31, 2024. Clients currently enrolled in Gilead's Advancing Access® PAP will have their coverage for TDF terminated on January 31, 2025.

Uninsured PrEP-AP Clients Prescribed TDF

As of January 1, 2025, PrEP-AP will cover generic TDF for clients enrolled in PrEP-AP as uninsured. Uninsured PrEP-AP clients will no longer be required to enroll in the Gilead Advancing Access® PAP Program if they are prescribed brand TDF. These clients can access their TDF prescriptions at a Prime Network Pharmacy. A PrEP-AP formulary update memo will be released when this update goes into effect.

Insured PrEP-AP Clients Prescribed TDF

There are no changes to PrEP-AP insured clients. PrEP-AP continues to cover co-pays for TDF for clients enrolled in PrEP-AP as insured. Most commercial health insurance plans in California should cover PrEP medications without cost-sharing; however, if clients have a co-pay for brand Truvada®, insured PrEP-AP clients must co-enroll in the Gilead Advancing Access® Co-pay Assistance Program. These clients can access their TDF prescriptions at a pharmacy in their health plan's network that is also a Prime Network Pharmacy.

PrEP-AP Clients Prescribed Other PrEP Medications

This change will not affect PrEP-AP clients prescribed emtricitabine-tenofovir alafenamide, brand name Descovy®, or long-acting cabotegravir, brand name Apretude.

If you have any questions regarding the information provided in this memo, please contact your PrEP-AP Advisor.

Thank you,

 ​​

Joseph Lagrama

ADAP Branch Chief

California Department of Public Health​